Sign in
CompletedNo phase

Development of a Cloud Platform for Advanced Diagnostics Based on Clinical and Omics Data.

Key facts

Who runs it
Istituto Giannina Gaslini
Where
Italy3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
73 people enrolled
Started
12 Mar 2025
Ended
31 Oct 2025
Type of study
Observational, 4 groups
Record updated
22 October 2026

Who can take part

Age
Up to 25 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age 0-25 years
  • Newly diagnosed active disease or unstable disease (ongoing attacks despite treatment), whether genetically confirmed or still undiagnosed
  • The patient or their legal representative provides informed consent to participate in the study, including undergoing omics analyses and agreeing to the sharing and use of their clinical and omics data for subsequent analyses
  • Monogenic SAID: Patients with clinical and genetic findings consistent with a monogenic SAID belonging to one of the following categories: inflammasomopathies, unfolded protein response (UPR) and cellular stress disorders, type I interferonopathies, actinopathies, NF-κB hyperactivation disorders, or DADA2. Physician Global Assessment (PGA) > 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels
  • Multifactorial/complex SAID: Patients with clinical manifestations consistent with PFAPA, SURF (as defined in Papa R et al., 2020), chronic recurrent multifocal osteomyelitis (CRMO)/SAPHO syndrome, or systemic juvenile idiopathic arthritis (sJIA). PGA > 2 on a 0-10 VAS and elevated CRP levels
  • Undifferentiated SAID (uSAID): Patients with clinical manifestations consistent with a SAID, after exclusion of defined monogenic or multifactorial/complex autoinflammatory diseases based on clinical and/or genetic findings. PGA > 2 on a 0-10 VAS and elevated CRP levels
  • Fibromyalgia (FM): Widespread pain with symptoms present for at least 3 months. Patients meeting the clinical criteria defined in Wolfe et al. (2016)

Who cannot take part

  • Inflammatory bowel diseases or other inflammatory conditions that may mimic SAIDs (e.g., haematological disorders, malignancies, and immunodeficiencies)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to explore how information from different types of biological tests, such as genetic, protein, and fat-related analyses, can help doctors better identify and distinguish patients with systemic autoinflammatory diseases (SAIDs), including undifferentiated or complex forms of these conditions (uSAIDs and SAIDs), as well as fibromyalgia. The goal is to improve diagnosis and help identify the most appropriate treatments and care options for each patient.

Read full original descriptionShow less

The study will also develop computer-based tools to identify important biological patterns in patients' medical records and laboratory results. These tools will help doctors interpret each patient's individual case and better understand their condition.

Finally, the study will bring together biological test results, clinical information, and the findings from these analyses in a single, comprehensive health record. This record will have an easy-to-use interface designed to support patients' care teams. Its usefulness in everyday clinical practice will then be evaluated.

The 4 groups in the trial

  • monogenic SAID

    Patients with clinical and genetic findings consistent with a monogenic SAID belonging to one of the following categories: inflammasomopathies, unfolded protein response (UPR) and cellular stress disorders, type I interferonopathies, actinopathies, NF-κB hyperactivation disorders, or DADA2. Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.

  • Multifactorial/complex SAID

    Patients with clinical manifestations consistent with PFAPA, SURF (as defined in Papa R et al., 2020), chronic recurrent multifocal osteomyelitis (CRMO)/SAPHO syndrome, or systemic juvenile idiopathic arthritis (sJIA). Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.

  • undifferentiated SAID

    Patients with clinical manifestations consistent with a SAID, after excluding defined monogenic or multifactorial/complex autoinflammatory diseases based on clinical and/or genetic findings. Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.

  • Fibromyalgia

    Widespread pain with symptoms persisting for at least 3 months. Patients meeting the clinical criteria defined in Wolfe et al. (2016).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development of a Cloud Platform for Advanced Diagnostics Based on Clinical and Omics Data - Sviluppo di Una Piattaforma Cloud Per la Diagnostica Avanzata Basata su Dati Clinico-omici
Record updated
22 October 2026